# Correction: Chronic administration of Metformin exerts cytostatic and cytotoxic effects via the PP2A-GSK3β-MCL-1 pathway by inhibiting the tmCLIC1 membrane protein in glioblastoma-initiating cells

**Authors:** Francesca Cianci, Ivan Verduci, Riccardo Cazzoli, Gaetano Cannavale, Guido Rey, Marina Veronesi, Beatrice Balboni, Matteo Ranucci, Luca Maria Giovanni Palloni, Federico Ballabio, Noemi Barsotti, Giorgia Ailuno, Alice Balboni, Sara Baldassari, Gabriele Caviglioli, Carlotta Tacconi, Carlo Camilloni, Stefania Girotto, Alessandro Fantin, Federica Barbieri, Andrea Cavalli, Massimo Pasqualetti, Tullio Florio, Saverio Minucci, Michele Mazzanti

PMC · DOI: 10.1186/s13046-025-03628-9 · Journal of Experimental & Clinical Cancer Research : CR · 2026-01-20

## Full-text entities

- **Genes:** PTPA (protein phosphatase 2 phosphatase activator) [NCBI Gene 5524] {aka PARK25, PP2A, PPP2R4, PR53}, MCL1 (MCL1 apoptosis regulator, BCL2 family member) [NCBI Gene 4170] {aka BCL2L3, EAT, MCL1-ES, MCL1L, MCL1S, Mcl-1}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932]
- **Diseases:** cytotoxic (MESH:D064420), glioblastoma (MESH:D005909)
- **Chemicals:** Metformin (MESH:D008687)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12817801/full.md

---
Source: https://tomesphere.com/paper/PMC12817801